Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma - PubMed
2 hours ago
- #CAR-T therapy
- #patient-reported outcomes
- #multiple myeloma
- First study to compare patient-reported outcome (PRO) trajectories between idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) CAR-T therapies for relapsed/refractory multiple myeloma (RRMM).
- PROs were assessed at multiple time points from baseline up to day 90 post-infusion; most PROs worsened or remained stable before day 7 and improved significantly thereafter.
- Key improvements post-day 7 included overall health-related quality of life, physical and functional well-being, fatigue, and physical and social function.
- Anxiety, sleep disturbance, pain interference, and pain intensity were stable initially and improved after day 7.
- Differences were observed between treatment groups in social well-being before day 7 and cognitive function after day 7, suggesting areas for further investigation.
- Study findings indicate similar PRO trajectories for both CAR-T types, with most patients experiencing initial decline or stability followed by recovery in multiple domains.